| Complete response of hepatocellular carcinoma with sorafenib and Y radioembolization. | |
| | |
MedLine Citation:
|
PMID: 20975882 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
Advanced hepatocellular carcinoma has a dismal prognosis, with a median overall survival of 7.9 months if untreated and of 10.7 months if treated with sorafenib. We present a case of advanced previously unresectable hepatocellular carcinoma in a 49-year-old man that achieved a pathologic complete response and was made amenable to surgery with sorafenib in combination with (90)Y radioembolization. The patient's survival was more than double the median for patients treated with sorafenib alone. |
| | |
Authors:
|
P K Chaudhury; M Hassanain; J M Bouteaud; T Alcindor; C G Nudo; D Valenti; T Cabrera; P Kavan; I Feteih; P Metrakos |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current oncology (Toronto, Ont.) Volume: 17 ISSN: 1198-0052 ISO Abbreviation: Curr Oncol Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-26 Completed Date: 2010-12-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502503 Medline TA: Curr Oncol Country: Canada |
Other Details:
|
Languages: eng Pagination: 67-9 Citation Subset: - |
Affiliation:
|
Department of Surgery, McGill University, and Hepatopancreatobiliary and Transplant Surgery Program, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Primary central nervous system T-cell lymphoma in aids patients: case report and literature review.
Next Document: A rare adverse skin reaction after 8 Gy of radiation therapy to the thoracic spine: case report and ...